Not Cipla, Not Lupin: 2 high-ROCE pharma ‘compounders’ with non-stop quarterly profit growth

While Nifty Pharma giants struggle with regulatory headwinds and pricing pressures, two outliers are quietly catching the attention of smart investors. These companies boast superior Return on Capital Employed (ROCE) and have maintained a rare streak of consistent quarterly profit growth throughout the last year. Could these be the first additions to your FY27 watchlist?